← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Selective beta-2-adrenoreceptor agonists
indacaterol
R03AC18
Forms & Strengths
- Inhalation powder, capsules: 75 mcg
- Inhalation powder, capsules: 150 mcg
- Inhalation powder, capsules: 275 mcg
Adult Dosing
- COPD: 75 mcg inhaled once daily via Neohaler
- Do not exceed 75 mcg once daily in the US (international approvals may include 150 mcg once daily)
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years of age
Indications
- Long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Mechanism of Action
- Ultra-long-acting beta2-adrenergic agonist (LABA)
- Stimulates intracellular adenylate cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle
Contraindications
- Primary treatment of asthma without an ICS
- Hypersensitivity to indacaterol or lactose (inhalation powder contains lactose)
Adverse Reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Cough
- Headache
- Tremor, tachycardia, and palpitations (beta-adrenergic effects)
Drug Interactions
- Other sympathomimetic agents: May potentiate adverse cardiovascular effects
- Beta-blockers: May antagonize the bronchodilatory effect of LABAs and induce severe bronchospasm
- QT-prolonging agents (e.g., MAOIs, tricyclic antidepressants): May increase risk of ventricular arrhythmias
- Hypokalemia-inducing agents (e.g., non-potassium-sparing diuretics): May exacerbate ECG changes and hypokalemia
Curated Content: Needs Vetting Before Put to Clinical Use